{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:18:42Z","timestamp":1788477522005,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG23760"],"award-info":[{"award-number":["IG23760"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG21408"],"award-info":[{"award-number":["IG21408"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ASO Alessandria","award":["MESOLINE"],"award-info":[{"award-number":["MESOLINE"]}]},{"name":"Fondazione Cassa di Risparmio di Torino","award":["ID 2018.0568"],"award-info":[{"award-number":["ID 2018.0568"]}]},{"name":"Fondazione Cassa di Risparmio di Torino","award":["ID 2020.1648"],"award-info":[{"award-number":["ID 2020.1648"]}]},{"name":"Intramural Grant Funding 2019"},{"name":"Intramural Grant Funding 2018"},{"name":"ERA-Net Transcan-2-JTC 2017","award":["TOPMESO"],"award-info":[{"award-number":["TOPMESO"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The combination of pemetrexed and cisplatin remains the reference first-line systemic therapy for malignant pleural mesothelioma (MPM). Its activity is moderate because of tumor aggressiveness, immune-suppressive environment and resistance to chemotherapy-induced immunogenic cell death (ICD). Preliminary and limited findings suggest that MPM cells have deregulated ubiquitination and proteasome activities, although proteasome inhibitors achieved disappointing clinical results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Here, we investigated the role of the E3-ubiquitin ligase SKP\/Cullin\/F-box (SCF) complex in cell cycle progression, endoplasmic reticulum (ER)\/proteostatic stress and ICD in MPM, and the therapeutic potential of the neddylation\/SCF complex inhibitor MLN4924\/Pevonedistat.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In patient-derived MPM cultures and syngenic murine models, MLN4924 and cisplatin showed anti-tumor effects, regardless of MPM histotype and BAP1 mutational status, increasing DNA damage, inducing S- and G2\/M-cell cycle arrest, and apoptosis. Mechanistically, by interfering with the neddylation of cullin-1 and ubiquitin-conjugating enzyme UBE2M, MLN4924 blocks the SCF complex activity and triggers an ER stress-dependent ICD, which activated anti-MPM CD8<jats:sup>+<\/jats:sup>T-lymphocytes. The SKP2 component of SCF complex was identified as the main driver of sensitivity to MLN4924 and resistance to cisplatin. These findings were confirmed in a retrospective MPM patient series, where SKP2 high levels were associated with a worse response to platinum-based therapy and inferior survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We suggest that the combination of neddylation inhibitors and cisplatin could be worth of further investigation in the clinical setting for MPM unresponsive to cisplatin. We also propose SKP2 as a new stratification marker to determine the sensitivity to cisplatin and drugs interfering with ubiquitination\/proteasome systems in MPM.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-022-02284-7","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T06:12:55Z","timestamp":1645596775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma"],"prefix":"10.1186","volume":"41","author":[{"given":"Iris Chiara","family":"Salaroglio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimas Carolina","family":"Belisario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bironzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeta","family":"Ananthanarayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Digiovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Sandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Facolmat\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Libener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Comunanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gazzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Taulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bussolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisella","family":"Righi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro Giulio","family":"Papotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Vittorio","family":"Scagliotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Riganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-3953","authenticated-orcid":false,"given":"Joanna","family":"Kopecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"2284_CR1","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3322\/caac.21572","volume":"69","author":"M Carbone","year":"2019","unstructured":"Carbone M, Adusumilli PS, Alexander HR, Baas P, Bardelli F, Bononi A, et al. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69:402\u201329. https:\/\/doi.org\/10.3322\/caac.21572.","journal-title":"CA Cancer J Clin"},{"key":"2284_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17:475\u201388. https:\/\/doi.org\/10.1038\/nrc.2017.42.","journal-title":"Nat Rev Cancer"},{"key":"2284_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.lungcan.2018.03.022","volume":"120","author":"J Kopecka","year":"2018","unstructured":"Kopecka J, Salaroglio IC, Righi L, Libener R, Orecchia S, Grosso F, et al. Loss of C\/EBP-\u03b2 LIP drives cisplatin resistance in malignant pleural mesothelioma. Lung Cancer. 2018;120:34\u201345. https:\/\/doi.org\/10.1016\/j.lungcan.2018.03.022.","journal-title":"Lung Cancer"},{"key":"2284_CR4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/ijc.32419","volume":"146","author":"V Milosevic","year":"2020","unstructured":"Milosevic V, Kopecka J, Salaroglio IC, Libener R, Napoli F, Izzo S, et al. Wnt\/IL-1\u03b2\/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5. Int J Cancer. 2020;146:192\u2013207. https:\/\/doi.org\/10.1002\/ijc.32419.","journal-title":"Int J Cancer"},{"key":"2284_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1398874","volume":"7","author":"C Riganti","year":"2017","unstructured":"Riganti C, Lingua MF, Salaroglio IC, Falcomat\u00e0 C, Righi L, Morena D, et al. Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. Oncoimmunology. 2017;7:e1398874. https:\/\/doi.org\/10.1080\/2162402X.2017.1398874.","journal-title":"Oncoimmunology"},{"key":"2284_CR6","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.jtho.2019.03.029","volume":"14","author":"IC Salaroglio","year":"2019","unstructured":"Salaroglio IC, Kopecka J, Napoli F, Pradotto M, Maletta F, Costardi L, et al. Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma. J Thor Oncol. 2019;14:1458\u201371. https:\/\/doi.org\/10.1016\/j.jtho.2019.03.029.","journal-title":"J Thor Oncol"},{"key":"2284_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000337","volume":"8","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8:e000337. https:\/\/doi.org\/10.1136\/jitc-2019-000337.","journal-title":"J Immunother Cancer"},{"key":"2284_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/mco.2013.202","volume":"2","author":"Y Xu","year":"2014","unstructured":"Xu Y, Wang C, Li Z. A new strategy of promoting cisplatin chemotherapeutic efficiency by targeting endoplasmic reticulum stress. Mol Clin Oncol. 2014;2:3\u20137. https:\/\/doi.org\/10.3892\/mco.2013.202.","journal-title":"Mol Clin Oncol"},{"key":"2284_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ctrv.2016.01.003","volume":"44","author":"DA Fennell","year":"2016","unstructured":"Fennell DA, Summers Y, Cadranel J, Benepal T, Christoph DC, Lal R, et al. Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev. 2016;44:42\u201350. https:\/\/doi.org\/10.1016\/j.ctrv.2016.01.003.","journal-title":"Cancer Treat Rev"},{"key":"2284_CR10","doi-asserted-by":"publisher","unstructured":"Riganti C, Kopecka J, Panada E, Barak S, Rubinstein M. The role of C\/EBP-\u03b2 LIP in multidrug resistance. J Natl Cancer Inst 2015;107:djv046. https:\/\/doi.org\/10.1093\/jnci\/djv046","DOI":"10.1093\/jnci\/djv046"},{"key":"2284_CR11","doi-asserted-by":"publisher","first-page":"8711","DOI":"10.2147\/CMAR.S194337","volume":"11","author":"RFH Walter","year":"2019","unstructured":"Walter RFH, Sydow SR, Berg E, Kollmeier J, Christoph DC, Christoph S, et al. Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma. Cancer Manag Res. 2019;11:8711\u201320. https:\/\/doi.org\/10.2147\/CMAR.S194337.","journal-title":"Cancer Manag Res"},{"key":"2284_CR12","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/jcmm.12279","volume":"18","author":"L Kubiczkova","year":"2011","unstructured":"Kubiczkova L, Pour L, Sedlarikova L, Hajek R, Sevcikova S. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J Cell Mol Med. 2011;18:947\u201361. https:\/\/doi.org\/10.1111\/jcmm.12279.","journal-title":"J Cell Mol Med"},{"key":"2284_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.canlet.2015.01.015","volume":"363","author":"KL Kuo","year":"2015","unstructured":"Kuo KL, Ho IL, Shi CS, Wu JT, Lin WC, Tsai YC, et al. MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies. Cancer Lett. 2015;363:127\u201336. https:\/\/doi.org\/10.1016\/j.canlet.2015.01.015.","journal-title":"Cancer Lett"},{"key":"2284_CR14","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nature07884","volume":"458","author":"TA Soucy","year":"2009","unstructured":"Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458:732\u20136. https:\/\/doi.org\/10.1038\/nature07884.","journal-title":"Nature"},{"key":"2284_CR15","doi-asserted-by":"publisher","unstructured":"Picco G, Petti C, Sassi F, Grillone K, Migliardi G, Rossi T, et al. Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer. J Natl Cancer Inst 2019;109:djw209. https:\/\/doi.org\/10.1093\/jnci\/djw209","DOI":"10.1093\/jnci\/djw209"},{"key":"2284_CR16","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.apsb.2019.09.005","volume":"10","author":"Q Yu","year":"2019","unstructured":"Yu Q, Jiang Y, Sun Y. Anticancer drug discovery by targeting cullin neddylation. Acta Pharm Sin B. 2019;10:746\u201365. https:\/\/doi.org\/10.1016\/j.apsb.2019.09.005.","journal-title":"Acta Pharm Sin B"},{"key":"2284_CR17","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","volume":"75","author":"G Guo","year":"2015","unstructured":"Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015;75:264\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1008.","journal-title":"Cancer Res"},{"key":"2284_CR18","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Research. 2010;70:440\u20136. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1947.","journal-title":"Cancer Research"},{"key":"2284_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ejmech.2017.03.076","volume":"133","author":"H Ma","year":"2017","unstructured":"Ma H, Zhuang C, Xu X, Li J, Wang J, Min X, et al. Discovery of benzothiazole derivatives as novel non-sulfamide NEDD8 activating enzyme inhibitors by target-based virtual screening. Eur J Med Chem. 2017;133:174\u201383. https:\/\/doi.org\/10.1016\/j.ejmech.2017.03.076.","journal-title":"Eur J Med Chem"},{"key":"2284_CR20","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"40","author":"D Shaloam","year":"2014","unstructured":"Shaloam D, Tchounwou PB. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 2014;40:364\u201378. https:\/\/doi.org\/10.1016\/j.ejphar.2014.07.025.","journal-title":"Eur J Pharmacol"},{"key":"2284_CR21","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.3892\/ol.2019.10596","volume":"18","author":"Y Zeng","year":"2019","unstructured":"Zeng Y, Iv YS, Pan QH, Zhou YG, Li H. An overactive neddylation pathway serves as a therapeutic target and MLN4924 enhances the anticancer activity of cisplatin in pancreatic cancer. Oncol Lett. 2019;18:2724\u201332. https:\/\/doi.org\/10.3892\/ol.2019.10596.","journal-title":"Oncol Lett"},{"key":"2284_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-021-01070-w","volume":"14","author":"YC Zheng","year":"2021","unstructured":"Zheng YC, Guo YJ, Wang B, Wang C, Mamun MAA, Gao Y, et al. Targeting neddylation E2s: a novel therapeutic strategy in cancer. J Hematol Oncol. 2021;14:57. https:\/\/doi.org\/10.1186\/s13045-021-01070-w.","journal-title":"J Hematol Oncol"},{"key":"2284_CR23","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/2159-8290.CD-14-1490","volume":"5","author":"E Chevet","year":"2015","unstructured":"Chevet E, Hetz C, Samali A. Endoplasmic reticulum stress-activated cell reprogramming in oncogenesis. Cancer Discov. 2015;5:586\u201397. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-1490.","journal-title":"Cancer Discov"},{"key":"2284_CR24","doi-asserted-by":"publisher","first-page":"17626","DOI":"10.1038\/s41598-017-17977-9","volume":"7","author":"F Cerruti","year":"2017","unstructured":"Cerruti F, Jocoll\u00e8 G, Salio C, Oliva L, Paglietti L, Alessandria B, et al. Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis. Sci Rep. 2017;7:17626. https:\/\/doi.org\/10.1038\/s41598-017-17977-9.","journal-title":"Sci Rep"},{"key":"2284_CR25","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1158\/1078-0432.CCR-12-3212","volume":"19","author":"ST Nawrocki","year":"2013","unstructured":"Nawrocki ST, Kelly KR, Smith PG, Espitia CM, Possemato A, Beausoleil SA, et al. Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clin Cancer Res. 2013;19:3577\u201390. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3212.","journal-title":"Clin Cancer Res"},{"key":"2284_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep16948","volume":"5","author":"IL Ho","year":"2015","unstructured":"Ho IL, Kuo KL, Liu SH, Chang HC, Hsieh JT, Wu JT, et al. MLN4924 synergistically enhances cisplatin-induced cytotoxicity via jnk and bcl-xl pathways in human urothelial carcinoma. Sci Rep. 2015;5:1\u201313. https:\/\/doi.org\/10.1038\/srep16948.","journal-title":"Sci Rep"},{"key":"2284_CR27","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.3892\/ol.2017.7616","volume":"15","author":"S Lin","year":"2018","unstructured":"Lin S, Shang Z, Li S, Gao P, Zhang Y, Hou S, et al. Neddylation inhibitor MLN4924 induces G2 cell cycle arrest, DNA damage and sensitizes esophageal squamous cell carcinoma cells to cisplatin. Oncology Lett. 2018;15:2583\u20139. https:\/\/doi.org\/10.3892\/ol.2017.7616.","journal-title":"Oncology Lett"},{"key":"2284_CR28","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00280-018-3582-z","volume":"81","author":"B Xu","year":"2018","unstructured":"Xu B, Deng Y, Bi R, Guo H, Shu C, Shah NK, et al. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification. Cancer Chemother Pharmacol. 2018;81:1083\u201393. https:\/\/doi.org\/10.1007\/s00280-018-3582-z.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2284_CR29","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.7150\/jca.44383","volume":"11","author":"H Yu","year":"2020","unstructured":"Yu H, Kim YM, Cho M. Cytoplasm-localized SIRT1 downregulation attenuates apoptosis and cell cycle arrest in cisplatin-resistant lung cancer A549 cells. J Cancer. 2020;11:4495\u2013509. https:\/\/doi.org\/10.7150\/jca.44383.","journal-title":"J Cancer"},{"key":"2284_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4081\/oncol.2014.256","volume":"8","author":"RK Mehmood","year":"2014","unstructured":"Mehmood RK. Review of cisplatin and oxaliplatin in current immunogenic and monoclonal antibodies perspective. Oncol Rev. 2014;8:36\u201343. https:\/\/doi.org\/10.4081\/oncol.2014.256.","journal-title":"Oncol Rev"},{"key":"2284_CR31","doi-asserted-by":"publisher","first-page":"e1583547","DOI":"10.1080\/2162402X.2019.1583547","volume":"8","author":"G Morcrette","year":"2019","unstructured":"Morcrette G, Hirsch TZ, Badour E, Pilet J, Caruso S, Calderaro J, et al. APC germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures. Oncoimmunology. 2019;8:e1583547. https:\/\/doi.org\/10.1080\/2162402X.2019.1583547.","journal-title":"Oncoimmunology"},{"key":"2284_CR32","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ccell.2020.01.011","volume":"37","author":"DJ McGrail","year":"2020","unstructured":"McGrail DJ, Garnett J, Yin J, Dai H, Shih DJH, Lam TNA, et al. Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell. 2020;37:371\u201386.e12. https:\/\/doi.org\/10.1016\/j.ccell.2020.01.011.","journal-title":"Cancer Cell"},{"key":"2284_CR33","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s12094-019-02275-9","volume":"22","author":"S Cedr\u00e9s","year":"2020","unstructured":"Cedr\u00e9s S, Ponce-Aix S, Iranzo P, Callejo A, Pardo N, Navarro A, et al. Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients. Clin Transl Oncol. 2020;22:1390\u20138. https:\/\/doi.org\/10.1007\/s12094-019-02275-9.","journal-title":"Clin Transl Oncol"},{"key":"2284_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.5732\/cjc.011.10319","volume":"31","author":"G Wang","year":"2012","unstructured":"Wang G, Chan CH, Gao Y, Lin HK. Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis. Chin J Cancer. 2012;31:169\u201377. https:\/\/doi.org\/10.5732\/cjc.011.10319.","journal-title":"Chin J Cancer"},{"key":"2284_CR35","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.cell.2013.06.048","volume":"154","author":"CH Chan","year":"2013","unstructured":"Chan CH, Morrow JK, Li CF, Gao Y, Jin G, Moten A, et al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell. 2013;154:556\u201368. https:\/\/doi.org\/10.1016\/j.cell.2013.06.048.","journal-title":"Cell"},{"key":"2284_CR36","doi-asserted-by":"publisher","first-page":"100673","DOI":"10.1016\/j.drup.2019.100673","volume":"49","author":"L Yan","year":"2020","unstructured":"Yan L, Lin M, Pan S, Assaraf YG, Wang ZW, Zhu X. Emerging roles of F-box proteins in cancer drug resistance. Drug Resistance Updat. 2020;49:100673. https:\/\/doi.org\/10.1016\/j.drup.2019.100673.","journal-title":"Drug Resistance Updat"},{"key":"2284_CR37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ebiom.2016.06.023","volume":"10","author":"M Benamar","year":"2016","unstructured":"Benamar M, Guessous F, Du K, Corbett P, Obeid J, Gioeli D, et al. Inactivation of the CRL4-CDT2-SET8\/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma. EBioMedicine. 2016;10:85\u2013100. https:\/\/doi.org\/10.1016\/j.ebiom.2016.06.023.","journal-title":"EBioMedicine"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02284-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-022-02284-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02284-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T06:15:41Z","timestamp":1645596941000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-022-02284-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2284"],"URL":"https:\/\/doi.org\/10.1186\/s13046-022-02284-7","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,23]]},"assertion":[{"value":"12 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of San Luigi Hospital (#126\/2016) and the Biological Bank of Mesothelioma, S. Antonio e Biagio Hospital, Alessandria, Italy (#9\/11\/2011). All animal procedures were performed in accordance with the national, institutional, and international law, policies, and guidelines (NIH guide for the Care and Use of Laboratory Animals -2011 edition-; European Economic Community (EEC) Council Directive 2010\/63\/UE; Italian Governing Law D. lg 26\/2014). The animal study was approved by the Ethical Committee of the University of Turin and by the Italian Ministry of Health (400\/2017-PR).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GVS received honoraria from AstraZeneca, Eli Lilly, MSD, Pfizer, Roche, Johnson & Johnson, Takeda; consulting or advisory role for Eli Lilly, Beigene, and AstraZeneca, received institutional research funding from Eli Lilly and MSD and received travel, accommodations from Bayer. SN has been part of the speaker bureau and advisor of AstraZeneca, Boehringer Ingelheim, Amgen, Beigene, Roche, MSD, Sanofi, Novartis, Takeda, Pfizer. PB has received honoraria from AstraZeneca, BMS, Beigene, MSD, Roche, Takeda; consulting or advisory role for AstraZeneca, and Roche; received institutional research funding from Roche; received virtual meeting registration from Amgen. CR has received research support from PharmaMar. The other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}